Skip to content

Welcome to Discover Pharma! Today is : October 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Pivotal Trial

  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Research & Development,Therapeutic Areas

    Novadip secures €10.4M to advance pivotal Phase 3 trial

    Novadip Biosciences has secured €10.4 million in convertible financing to [...]

    September 21, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Claris Bio raises $118 million to advance potential first drug treatment for LSCD

    Claris Biotherapeutics has raised $118 million in a Series B [...]

    July 29, 2026
  • Clinical & Regulatory,Medical devices,Research & Development

    Xeltis passes halfway mark in US trial of haemodialysis vascular access device

    Xeltis has passed the halfway enrolment mark in its US [...]

    July 3, 2026
  • Drug Delivery & Formulation

    Carthera hits major recruitment milestone in glioblastoma trial using BBB-opening ultrasound device

    Carthera has enrolled the first 100 participants in its Sonobird [...]

    April 24, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • BridgeBio gets FDA Priority Review for oral infigratinib in achondroplasia
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • ViiV’s Cabenuva achieves superior viral suppression in CROWN Phase 3b study
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Shift Bioscience publishes AI virtual cell framework for target discovery
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top